Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma
| العنوان: | Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma |
|---|---|
| المؤلفون: | Yingxin Xu, Eleanor Paul, Patricia Guyot, Chieh-I Chen, Andreas Kuznik, Medha Sasane, Sam Keeping, Shannon Cope, Gerasimos Konidaris, Ali Mojebi, Dieter Ayers, Kokuvi Atsou |
| المصدر: | Journal of Managed Care & Specialty Pharmacy. 27:1513-1525 |
| بيانات النشر: | Academy of Managed Care Pharmacy, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Oncology, medicine.medical_specialty, Cutaneous squamous cell carcinoma, business.industry, Cost-Benefit Analysis, Health Policy, Cell, Antibodies, Monoclonal, food and beverages, Pharmaceutical Science, Pharmacy, Cost-effectiveness analysis, Pembrolizumab, Antibodies, Monoclonal, Humanized, Progression-Free Survival, United States, Antineoplastic Agents, Immunological, medicine.anatomical_structure, Internal medicine, Carcinoma, Squamous Cell, medicine, Advanced disease, Humans, Surgical excision, business |
| الوصف: | BACKGROUND: Most cutaneous squamous cell carcinomas (CSCCs) can be treated with surgical excision or radiation; however, approximately 1% of patients develop advanced disease. In 2018, the FDA appr... |
| تدمد: | 2376-1032 2376-0540 |
| DOI: | 10.18553/jmcp.2021.21164 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::663ed31a85930fb57c9c0d37149a2463 https://doi.org/10.18553/jmcp.2021.21164 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....663ed31a85930fb57c9c0d37149a2463 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 23761032 23760540 |
|---|---|
| DOI: | 10.18553/jmcp.2021.21164 |